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1. Introduction   
Psoriasis is an immuno-mediated condition whose pathogenesis is still unclear and that in 
head and neck area presents six specific aspects that justify the title of this chapter: 1) 
visibility of the lesions and their impact on quality of life (QOL); 2) the very common 
involvement of the scalp; 3) the difficulty of the treatment; 4) the aberrant epidermal-
mesenchymal interactions theory; 5) the rare mucous occurrence and the PPP-tonsil-related 
disease; 6) the significantly increased risk of head and neck cancer in men with Psoriasis. 
2. Visibility and the impact on quality of life  
Visibility of head and neck Psoriasis has a considerable impact on patients’ QOL. The 
differential diagnosis for pustular skin disorders is extensive but facial Psoriasis more 
commonly affects eyebrows, the skin between the nose and  the upper lip, the upper 
forehead and the hairline. Scalp Psoriasis is very common. Multiple instruments have been 
used to determine the severity of scalp Psoriasis and tools for patient self-assessment have 
also been developed (Psoriasis Area and Severity Index or PASI, Psoriasis Scalp Severity 
Index or PSSI, Body Surface Area or BSA, Physicians' Global Assessment or PGA, Lattice 
Physician Global Assessment or LS-PGA, and Self-assessed Psoriasis Area and Severity 
Index or SAPASI) but none of the severity scores used for Psoriasis meets all of the 
validation criteria required for an ideal score. However the PASI score is the most 
extensively studied (Puzenat & al, 2010). 
While head represents only 10% of the whole body’s surface, consequences of scalp Psoriasis 
are disproportionate to its extension as it can be seriously debilitating inducing important 
social and emotional distress. 
Although it is unclear why initial scalp involvement is so common, scalp tissue has unique 
features that may promote its vulnerability to psoriatic lesions. For example, its high 
follicular density provides a dark, warm and moist environment that reduces environmental 
UV exposure which normally would limit lesion development. In addition, inflammation-
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promoting microorganisms flourish in the sebum-rich setting of the scalp and, as seen in one 
study, an association with the severity of scalp disease was suggested to be related to 
isolation of Malassezia globosa yeast from patients scalp (Gupta & al., 2004).  
Additional inflammation may be triggered or exacerbated by frequent friction and trauma 
to the scalp (Koebner phenomenon: psoriatic lesions as consequence of trauma in psoriatic 
patients) from brushing or use of styling implements. 
Psoriasis of the eye is extremely rare.  When it does occur, it can cause inflammation, 
dryness and discomfort. It may cause vision impairment. When Psoriasis affects the eyelids, 
scales may cover lashes and topical antibiotics may be used to treat infection.  
Psoriasis generally affects the external auditory canal without involvement of the ear or 
behind the eardrum but can cause scale buildup that can block the auditory canal with 
subsequent temporary hearing loss. 
Rarely Psoriasis appears on the gums, the tongue, inside the cheek and the nose or on the 
lips. The lesions in these areas are usually white or gray and can be relatively uncomfortable 
as they can cause chewing and swallowing discomfort. 
When Psoriasis involves the face, it can be much more disabling and can severily decrease 
patient’s QOL. Facial Psoriasis is difficult to treat and is associated with severe cutaneous 
disease. In fact, patients who have a long history of Psoriasis or an early age of onset are 
more likely to suffer from facial involvement. Facial Psoriasis may also be associated with 
pruritus, psoriatic arthritis, and with a family history of Psoriasis. 
Various clinical manifestations of Psoriasis make it more than a dermatological nuisance, as 
it interferes with many normal daily activities, such as use of hands, walking, sleeping, and 
sexual activity. At least 30% of patients contemplate suicide, which places Psoriasis on par 
with other major medical diseases such as depression, heart disease and diabetes (Krueger, 
2001). 
Alexithymia was originally defined as the inability to recognize and verbalize emotions. It is 
characterized by an emptiness of feelings, poverty of imagination or of a life fantasy and by 
difficulties in communicating with other peoples, as well as lack of positive emotions and a 
high prevalence of negative emotions. Its presence has been incriminated in genesis and 
maintenance of various psychosomatic pathologies.  
As patient’s psychological dimension seems to be related to the onset of the illness, to its 
evolution and to its prognosis, Psoriasis is classified among psychosomatic pathologies too.  
In this perspective Alexithymia does not appear to be simply a condition related to 
Psoriasis, but a worsening of patient’s condition, exposing him to other psychosomatic 
diseases and alcoholism and to a worsening of his global prognosis. That’s why 
psychological approach in treatment favouring expression of patient’s emotions and 
opening a symbolic dimension is as important as the biological approach and is necessary 
for improvement (Masmoudi, 2009). 
A recent cohort study (Gelfand & al., 2011) has also shown that severe Psoriasis (defined as 
Psoriasis patients with a history of systemic therapy) is associated with an increased risk of 
mortality as male and female patients in the study died 3.5 and 4.4 years younger 
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respectively than those without Psoriasis (even after adjustment for classical risk factors of 
mortality). Hence Psoriasis is a major public health problem.  
The data analysis suggests that a minimum of two summary scores (one for skin and one for 
joints), and potentially a third for nails, are required to accurately assess severity across the 
full spectrum of psoriatic disease. The optimal design of such assessment tools remains the 
objective of many research projects, with efforts continuing to identify the most meaningful 
contributing elements that define the full spectrum of the psoriatic disease state (Wittkowski 
& al., 2011). 
2.1 Addictions and Psoriasis 
Association between Psoriasis and addictive disorders is a longtime suspect and several 
studies are supporting association of Psoriasis and alcohol, and of Psoriasis and tobacco. 
Association between Psoriasis and alcohol seems not to be influenced by gender and shows 
a dose-effect relation. The most striking link between cigarette smoking and Psoriasis has 
been established in Palmo-Plantar Pustulosis (PPP). This link also seems to exist for other 
forms of Psoriasis with a dose-effect relation.  
The relationship between cigarette smoking and Psoriasis has been the subject of several 
studies. It was showed that cigarette smoking represents a significant risk factor for 
appearance of Psoriasis, especially in women, in a case about five, and it has been pointed 
out  that risk increases with the number of cigarettes consumed per day and increases in 
those who smoke 20 or more daily. The risk would increase further in those who have a 
family history of this disease. Also for PPP seems to be a relation to cigarette smoking, with 
a risk factor 7.2 times higher in smokers than in non smokers. The report is based on 
leukocyte neutrophil counts: PPP is a neutrophilic dermatosis and cigarette smoke increases 
peripheral neutrophil counts and alters it in morphological and functional way.  
Cigarette smoking may be involved in the high prevalence of lung and oral cancer and 
cardio-vascular disorders in psoriatic patients. The association between alcohol and 
development of plaque-type Psoriasis is complex and confusing because many of the initial 
studies did not control for confounding factors such as tobacco use.   
There are a number of difficulties in the assessment of the correlation between Psoriasis, 
cigarette smoking and alcohol, and even more so in establishing a causal or etiologic 
relationship between the three because of several confusing factors (Meyer &al., 2008).  
Alcohol-controlled studies suggest that women who are smokers have an up to 3.3-fold 
increased risk of developing plaque-type Psoriasis. Men who are smokers do not exhibit 
such an increased risk, but studies have shown that smoking more than 10 cigarettes per 
day by men who are Psoriasis patients may be associated with a more severe expression of 
disease in their extremities. In addition, smoking among both men and women who are 
Psoriasis patients has been shown to reduce improvement rates.  
Dermatologists are not only the sentinels for early diagnosis of psoriatic arthritis, but also 
for metabolic complications such as dyslipidemia or diabetes. Moreover, they need to keep 
in mind interactions between (systemic) anti-psoriatic drugs and the co-medication of their 
patients as well as possible consequences of these co-medications on the course of Psoriasis 
(Behnam & al., 2005).  
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The association between Psoriasis and alcoholism represents one of the major 
psychodermatological issues where a multidisciplinary approach (including dermatologist, 
psychiatrist, psychologist and others) is crucial for optimal outcome. Psoriasis is associated 
with an increased risk of comorbidity and mortality compared to the general population. It 
appears that patients with Psoriasis have a higher prevalence of metabolic disorders such as 
diabetes, hypertension, obesity, and hyperlipidemia, as well as a higher frequency of 
cigarette smoking. These concomitant diseases can complicate the treatment of Psoriasis. 
3. The very common involvement of the scalp 
The estimated prevalence of Psoriasis worldwide is 0.3-5%, depending on ethnic origin 
(Naldi, 1994; Valdimarsson, 2007). In a retrospective analysis in children was present scalp 
involvement in 48% on 125 patients by Stefanaki & al. (2011) and in 50.3% on 137 patients 
(most common initial site affected) by Wu & al. (2010) . 
Psoriasis of the scalp is estimated to occur in 40-90% of patients with Psoriasis. Up to 79% of 
patients with chronic plaque Psoriasis may have scalp involvement (Farber & Nall, 1992). It 
can be mild to severe, frequently itchy and so cosmetically embarrassing to affect patient’s 
QOL adversely. Treatment is often prolonged for a long period of time and can be another 
cause of worsening of patient’s QOL because of hair staining, face irritating, messy, time-
consuming and cosmetically unacceptable applications prescribed. 
As with Psoriasis elsewhere on the body, skin cells grow too quickly on the scalp and cause 
red lesions to be covered with scales. Scalp Psoriasis can be very mild with slight and fine 
scaling but can also be severe with thick, crusted plaques covering the entire scalp. Psoriasis 
can extend beyond the hairline onto the forehead, the back of the neck and around the ears.  
The scalp is frequently involved in patients with Psoriasis vulgaris but rarely it is the only 
site affected. Lesions look like an erythematous crown with net margins covered by dry 
silvery-white scales. They are located at the hairline in the fronto-temporal, parietal or 
occipital areas (where, often, the erythematous component is more pronounced) and are 
associated to scaling-scratching squamous lesions. In the fronto-temporal regions, 
particularly in young subjects, the spots extend beyond the scalp involving the skin of the 
forehead and ear. In patients with a long history of scalp Psoriasis the confluence of many 
spots and the scant evidence of the erythematous component leads to the formation of a real 
shell that can cover the entire scalp. In other cases, silvery-white scales are seen on a 
widespread dry pityriasiform furfuracea-like desquamation, sometimes showing follicles. 
The spots do not produce alopecia and hairs are not incorporated by squamous heaps but in 
the less restrictive forms the pseudotinea amiantacea can be seen. This lesion, once 
considered a variant of impetigo, is characterized by the presence of small opaque white 
adherent scales similar to asbestos, that incorporate the proximal part of the hair shaft. 
Psoriasiform lesions localized to the face often represent the extension of scalp lesions to the 
brow, the temporal regions, the ears and the retroauricular fold where it is observed a 
tendency to fissures. The involvement of the face in the course of Psoriasis is considered an 
index of extended or severe disease as in the case of erythrodermic Psoriasis. Rarely small 
droplike lesion in the face can be seen in case of eruptive Psoriasis; in case of mild forms of 
Psoriasis Vulgaris (minimal Psoriasis) instead, the eyelid involvement by small patches of 
whitish scales is characteristic. Psoriasis of the ear is characterized not only by the 
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involvement of the auricle but also by the involvement of external auditory canal by heaps 
of scales that can stamp it. Diagnosis of SeboPsoriasis, that is characterised by the presence 
of yellowish-white unctuous scales can be put when psoriasiform lesions are localized 
exclusively in seborrheic areas of the face (naso-labial fold, glabella and eyebrows, auricle 
and retroauricular fold) and are associated with similar lesions of the hairline and the 
presternal area. This clinic form, on the border between Psoriasis Vulgaris and Seborrheic 
Dermatitis, is considered  a Psoriasis arisen on patches of Seborrheic Dermatitis because of 
the Koebner phenomenon.  
Family history may predispose patients to scalp Psoriasis. In an analysis of Psoriasis genes 
in an Icelandic patient population, 296 of 1,000 Psoriasis patients experienced onset of 
Psoriasis on the scalp. Cluster analysis (Karason & al., 2005) of this subset of patients 
determined that 198 patients fit within 79 families and determined a linkage to 
chromosome 10. The familial nature of Psoriasis has long been recognized with evident 
intra and interfamilial variability. Thirty nine individual with Psoriasis (25 men and 14 
women) from 9 Tunisian unrelated multiplex families (in Tunisian population the 
estimated prevalence of Psoriasis is of 3%) were investigated during a study period of 1 
year (Ammar & al., 2009). The common form of Psoriasis was discovered in 37 cases. The 
nails, the scalp, the mucous membranes were involved respectively in 21, 12 and 13 cases. 
The Psoriasis was severe in 11 cases. 
Methods used to diagnose scalp Psoriasis vary in sensitivity, reproducibility, and 
invasiveness. Recently has been introduced a videodermoscopy scalp Psoriasis severity 
index (VSCAPSI) for evaluation of scalp Psoriasis (Rossi &al., 2011). This index is 
particularly useful in mild and moderate forms that often are not clinically appreciable. 
VSCAPSI takes into account extension of the area of the scalp affected, the presence and 
morphology of vascular patterns, erythema and desquamation. Videodermoscopy images 
obtained between November 2009 to June 2010 from 900 participants with various scalp and 
hair disorders were reviewed for distinguishing features. During the 2010 Italian congress 
on Psoriasis, in order to assess the reproducibility and efficacy of the VSCAPSI, 146 
dermatologists were asked to evaluate 16 videodermoscopy images of scalp Psoriasis using 
the VSCAPSI. Of the 900 patients, 85 new cases of scalp Psoriasis were diagnosed. The other 
815 patients were found to be suffering from different scalp and hair diseases. Of 146 
dermatologists, 28 did not recognize erythema, 15 desquamation and 7 the vascular 
patterns. The VSCAPSI provides an important tool for early diagnosis, differential diagnosis 
and follow-up and screening. 
3.1 Histology of head and neck Psoriasis: Gross findings 
Head and neck Psoriasis (in the form of the so-called Psoriasis vulgaris or plaque type of 
Psoriasis and guttate Psoriasis) commonly involves the skin surface of the scalp and the face 
(eyebrow, nose, upper lip, forehead, and hairline) and presents as papules, well-demarcated 
erythematous plaques with a scaly surface or as papulo-squamous lesions covered by fine 
silvery-white and loosely adherent scales. The amount and thickness of the scales is variable 
such are the plaques, ranging in size from few to several centimeters, with coalescence of 
smaller plaques into larger and sometimes fissured lesions. On the other hand, less thick 
plaques and less scaly lesions are commonly encountered in children with face psoriatic 
localization compared with adults. Pustular forms of Psoriasis are rarely described on the 
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face as annular or circinnate and pustular lesions on an erythematous background with an 
acute, subacute or chronic clinical course. Pustular eruptions are frequently associated with 
a classic form of skin Psoriasis, and both hair loss and involvement of tongue mucosal 
surface may be appreciated. Oral localizations, less commonly observed in children than in 
adults, appear as pustular and hyperemic lesions within a geographic and fissured tongue. 
In such a localization, infections, smoking and physical agents all may affect the course and 
duration of Psoriasis and may cause dysphagia. Unusual mucosal (nose, oral cavity) or 
ocular localizations are commonly described in patients with otherwise usual skin psoriatic 
dermatitis. Mucosal lesions show a non-specific macroscopic appearance ranging from 
erythematous and slightly raised lesions to a white annular, serpiginous and ulcerated 
pattern that may disappear quickly, with no obvious clinical symptoms, or may have 
exacerbations and remissions similar to skin lesions. Pustular forms, mixed white and 
erythematous lesions, ulcerative, vescicular and indurated lesions, multiple annular coin-
sized lesions, gray, yellowish, translucent and silvery-white forms are described with 
macroscopic findings similar to several so-called psoriasiform benign and malignant 
conditions involving the oral cavity. In this setting, the diagnosis mainly rely on an 
interdisciplinary clinical and histological approach with a crucial role played by the 
microscopic findings on mucosal biopsy. Psoriasis vulgaris may also be associated to oral 
localizations such as the case of geographic tongue and the stomatitis areata migrans. 
Patients with Psoriasis rarely develop uncommon ocular manifestations such as uveitis, 
blepharitis and conjunctivitis as a result of changes, alterations and dysfunctions of 
conjunctival surface, tear film and meibomiam gland changes. 
3.2 Microscopic findings 
Variabilities in clinical macroscopic findings of Psoriasis reflect different histologic pictures 
with relation to the stage of the disease. Generally, early stages show more typical and 
pathognomonic microscopic clues to the diagnosis than that of the advanced and fully 
developed lesions. Moreover, histologic differences could also be noted in psoriatic lesions 
affecting mucosal surfaces. 
In its classic histologic appearance, cutaneous Psoriasis shows achantosis (thickened of 
epidermal layers) and parakeratosis (retention of cell nuclei in stratum corneum) of the 
epidermis, with thin or loss of granular cell layer, downward elongation of rete ridges and 
thinning of the epidermis overlying the dermal papillae that shows edema and small vessels 
close to the epidermis. The latter condition underlies the so-called Auspitz sign: when the 
silvery scales (parakeratotic layers) are removed from the plaque (epidermal achantosis), 
small pinpoint bleeding (from dermal capillaries) is seen. 
The inflammatory cutaneous infiltrate of Psoriasis is characterized by neutrophils and 
lymphocytes throughout the superficial papillary dermis. Activated CD3+ T cells are mainly 
observed around small papillary vessels and are admixed with neutrophils and 
macrophages. Neutrophils and lymphocytes can migrate upwards from the dermis to the 
epidermis and in parakeratotic layers (exocytosis). Collections of intraepithelial neutrophils 
(Munro abscesses) and those arranged in the epidermis in a network of degenerated 
keratinocytes (spongiform pustule of Kogoj) are characteristics of Psoriasis but not always 
present nor specific to the disease. 
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In the pustular form of Psoriasis, such a collection of neutrophils occurs as characteristic 
macropustules (abscesses), while epidermal and dermal changes are similar to those seen in 
Psoriasis vulgaris. The so-called eruptive or guttate Psoriasis, with small and numerous red 
papules and an acute onset on clinical examination, shows similar microscopic findings to 
that of early Psoriasis vulgaris lesions unless the same degree of achantosis.  
Mucosal localizations show a more variable histological presentation ranging from classic 
hyperparakeratotic lesions, with thinning of the suprapapillary plate and mixed 
inflammatory infiltrate with neutrophils exocytosis to mild and quickly self-limited 
erythematous inflammatory conditions with capillaries engorgement but without 
microabscess formation. Similar microscopic characteristic are shared by different 
inflammatory mucosal diseases generally known as psoriasiform mucositis or psoriasiform 
lesions. In such instances, histological distinction between Psoriasis and other inflammatory 
mucosal entities cannot be made with confidence unless mucosal lesions are associated to or 
are coincident with cutaneous psoriatic dermatitis and additional data (family history, HLA 
typing) are available. 
3.3 Differential diagnosis 
Although the diagnosis of Psoriasis mainly rely on clinical settings, histological 
evaluation should be used to confirm the diagnosis as well as to evaluate unusual clinical 
lesions and to exclude benign and malignant conditions that may mimic Psoriasis or may 
be associated to it. 
On the other hand, microscopic findings alone should pose problems in differential 
diagnosis with other inflammatory disorders as well as in the evaluation of the phase of 
Psoriasis normally evolving through early, advanced and later lesions with a different 
microscopic variability with lesion’s age and activity. 
Skin psoriatic manifestations should sometimes require a differential diagnosis from 
dermatoses such as lichen planopilaris, florid seborrheic dermatitis and discoid lupus 
erythematosus.  
On the other hand, differential diagnosis of oral localization of Psoriasis could also consider 
Reiter’s syndrome, erythema migrans, benign migratory glossitis, oral lichen planus and 
other inflammatory conditions generally described as psoriasiform lesions. 
Clinical data alone may be inadequate such as the case of Koebner phenomenon that could 
be present in lichen planus.  
In this settings, the macroscopic characteristics of cutaneous psoriatic lesions (well defined 
elevated lesions, with silvery-white or micaceous scale), the clinical data (symmetrical 
distribution, Auspitz sign, patient’s history reporting itchy, skin scaling and peeling, lesions 
at site of injury or trauma) and the classic histologic findings may all contribute to a 
definitive diagnosis of Psoriasis.  
Oral lichen planus, mainly occurring in adults, appears as bilateral plaques, papules and 
erythematous-atrophic or ulcerated lesions on the oral mucosa, gingivae (desquamative 
gingivitis) and tongue. Oral white striations (so-called Wickham striae) may coincide with 
cutaneous lesions on the scalp, laryngeal and esophageal mucosa or less frequent 
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conjunctival lesions. Skin involvement of the scalp (lichen plano-pilaris) appears as scarring 
alopecia and violaceous and erythematous papules with hair loss. On histologic 
examination, more irregular acanthosis, prominent granular cell layer and dense sub-
epithelial T-cell CD8+ inflammatory infiltrate along with damage of basal keratinocytes 
represent clues to the diagnosis in contrast to Psoriasis. Moreover, since patients with oral 
lichen planus could develop oral squamous cell carcinoma and commonly show a 
significant local morbidity with negative impact on QOL, a proper diagnosis based on 
clinical and histological findings is mandatory. 
Discoid lupus erythematosus may sometimes be responsible for unusual manifestations in 
head and neck localizations that can mimic several skin diseases (Psoriasis, acne rosacea, 
lichen planopilaris) or be associated with liken planus-like lesions and Psoriasis. 
Nonetheless, clinical findings are usually characteristic as erythematous papules and 
plaques that progress to scaling lesions with pigmentary changes (central hypopigmentation 
and peripheral hyperpigmentation) in a centrifugal spread. Cutaneous scalp lesions may 
result in permanent alopecia with atrophy and scarring (localized form of discoid lupus 
erythematosus) with histologic picture similar to that of lichen planopilaris. Rare mucosal 
involvement are described with clinical and microscopic characteristic that may simulate 
lichen planus lesions. In this setting, laboratory data (hematologic and serologic 
abnormalities frequently observed in widespread discoid lupus erythematosus) along with 
meticulous clinical attention and microscopic findings (essentially dependent on familiarity 
with these lesions) can pose a correct diagnosis.  
Psoriatic lesions may also not look much different from those caused by seborrheic 
dermatitis, a papulo-squamous disease of the scalp, face and trunk. In its facial localization, 
the disease may be associated with squamous blepharitis, a chronic inflammation of the lid 
margins with small white scales accumulated among the lashes, or may present as mild 
scaling to widespread crust adherent to the skin of the scalp, forehead, neck and 
postauricolar skin. Secondary infections may occur as eczematoid dermatitis. Microscopic 
picture shows a more irregular acanthosis than that seen in psoriatic lesions along with 
spongiosis and follicular ostia involvement.  
The guttate variety of Psoriasis may appears as an acute exanthema in young adults, often 
associated to streptococcal pharyngitis, with papules on the face similar to those seen in 
psoriasiform drug eruption. The latter condition is also known as localized drug reactions 
related to medications and usually involving the face, chest and back with a papulo-
erythematous or vescicular and pustular appearance. Similarly, psychogenic and emotional 
factors, infections and environmental factors may all contribute to the development of 
cutaneous lesions similar to those seen in Psoriasis or may be related to increase in Psoriasis 
activity and severity. 
Histologic overlapping in such cases, with lacking of microscopic characteristic features, 
require a correct clinical evaluation in the differential diagnosis of these conditions.  
Differential diagnosis of head and neck Psoriasis, in both cutaneous and mucosal 
localizations, should also consider preneoplastic and neoplastic conditions. Since head and 
neck Psoriasis is more often a chronic and long standing process, frequently associated with 
severe cutaneous disease and difficult treatment, a significant risk of cancer has been noted. 
Such an association could be related to the reactive epidermal hyperproliferation seen in 
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psoriatic lesions along with keratinocytes activation and expression of molecules involved in 
cell proliferation. In particular, basal cell and squamous cell carcinomas are frequently 
reported and should be taken into account when evaluating psoriatic patients. 
Moreover, malignant conditions should be ruled out as is the case of the rare acrokeratosis 
paraneoplastica (Bazex syndrome). The disease can be associated with head and neck and 
upper aerodigestive tract squamous cell carcinomas and differs from Psoriasis in its 
localizations (erythematous squamous plaques or scaly patches of earlobes, helices and tip 
of the nose along with similar lesions in the extremities and nail dystrophy) and lack of 
histological findings typical of Psoriasis. 
Investigators use several physical examination measures to assess clinical features and 
severity of Psoriasis and psoriatic arthritis (PsA) in clinical trials, clinical registries, and 
clinical practice; however, no relevant training modules are widely available to teach and 
standardize the performance of these measures. At a GRAPPA (Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis) meeting adjacent to the 2009 International 
Federation of Psoriasis Associations in Stockholm, members were updated on the 
development status of online training videos of Psoriasis and PsA examination measures. 
Dermatology assessment modules include the PASI, the PGA, the BSA, the original and 
modified Nail Psoriasis Severity Index (NPSI), the Palmar-Plantar Pustular Psoriasis Area 
and Severity Index (PPP-PASI), and the PSSI. Rheumatology modules include assessment of 
tender and swollen joint counts used in the American College of Rheumatology criteria, 
Disease Activity Score, and other composite arthritis scores; enthesitis assessment used in 
various enthesitis scoring systems; dactylitis; and spine disease. Each module will include 
background information for each measure, diagrams and photographs to emphasize 
teaching points, demonstration video of examination where applicable, and an optional 
examination at the end. Future plans include evaluating the modules for their influence on 
interrater and intrarater reliability and development of additional modules (Callis Duffin & 
Mease, 2011). 
4. The difficulty of the treatment  
Head and neck Psoriasis treatment is still a challenge because its difficult to get topical 
agents through hair to be absorbed by the scalp. In fact, scalp is not susceptible to many 
topical Psoriasis treatment or phototherapy because hair prevent adequate contact with the 
affected tissue. Moreover current therapies can only bring some relief to the symptoms 
without any cure to the disease and treatments can carry important side effects in face of 
high therapeutic costs. 
Medications for scalp Psoriasis include those to be left on the scalp and wash off products. 
Left on products are gels, lotions and ointments containing steroids, coal tar, salicylic acid or 
vitamin D analogs.  
Wash off products are shampoos containing coal tar, salicylic acid, sulfur, selenium, 
ketoconazole or zinc pyrithione. Recently, Handa (2010) proposed a treatment algorithm for 
scalp Psoriasis (see Tab. 1), dividing a first line and a second line therapies.  
In 2009 van de Kerkhof & al. divided treatment of scalp Psoriasis into four phases. First 
phase involves descaling using salicylic acid or urea preparations. The second phase is the 
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clearing phase in which topical corticosteroids, vitamin D analogs, tar, dithranol, antifungal 
treatment, ultraviolet B light therapy or systemic treatment are used. The third phase is 
stabilization using a steroid-sparing vitamin D analog during the week and a super potent 
topical corticosteroid at weekends. Finally, the fourth phase is maintenance, using a vitamin 
D analog alone or with a tar shampoo. 
 
First line therapies 
Salicylic acid/Urea 
Topical corticosteroids (short term use) 
Calcipotriol 
Dithranol/Anthralin 
Coal tar (Shampoo/pomade) 
Tazarotene 
Combination therapies 
Second line therapies (for recalcitrant or severe disease) 
Phototherapy 
Systemic drugs (Methotrexate, Acitretin, Cyclosporine) 
Biologics 
Table 1. Treatment algorithm for scalp Psoriasis (from Hanna S., 2010) 
4.1 Corticosteroids 
Topical corticosteroids are the recommended first-line therapy for short-term use. Response 
to treatment is quick but high potential for side effects, such as atrophy, striae, 
telangiectasias and tachyphylaxis, limits the period of use. These side effects are virtually 
never seen in the scalp. Use of potent steroids (twice a day) should be limited to 4 weeks. 
The choice of preparation such as ointment, cream, gel, lotion, foam, spray or shampoo 
should be patient oriented.  
In any single patient the lowest strength preparation that allows clinical clearing should be 
used for the shortest time, in order to minimize side effects and tachyphylaxis. Nevertheless, 
long-term use of mid-potency preparations or intermittent use of potent steroids is more 
commonly practiced by physicians. Clobetasol propionate (CP) 0.05% and betamethasone 
dipropionate 0.05% are the most potent topical corticosteroid preparations currently used. 
Exceptionally intralesional corticosteroids can be used for one or two localized patches not 
responding to topical steroids. Foam vehicles are the new alternatives to traditional topical 
preparations because of the advantage of minimal residue and increased ease of application. 
They are absorbed more rapidly, have a higher bioavailability, are not associated with 
suppression of the hypothalamic pituitary adrenal (HPA) axis and once-daily 
administration has been seen to be as effective as twice daily administration. They are also 
associated with better patient compliance. CP foam 0.05% is generally as effective as CP 
solution for scalp Psoriasis and may produce superior results against scaling. Dose is limited 
to 50 g/week. Mid-potency corticosteroid betamethasone valerate (BMV) has also become 
available in a new thermolabile, low-residue foam vehicle, BMV 0.12% foam. In a recent 
study BMV foam produced greater improvement in the primary signs of scalp Psoriasis than 
BMV lotion, placebo or other standard topical therapies (Stein, 2005). Shampoo preparations 
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are another new development. When clobetasol shampoo 0.05% was tried in a patient 
experience program, 50% of the patients said that the shampoo was easy to use and did not 
interfere with their daily routine. Almost 90% of patients found the shampoo better than 
other prescriptions they had used before for their scalp Psoriasis.  
Medication used to treat facial Psoriasis should be applied carefully and sparingly; creams 
and ointments can irritate eyes. Because facial skin is delicate, prolonged use of steroids may 
cause it to become thin, shiny and/or prone to enlarged capillaries. Treatment with steroids 
is safe if a careful treatment schedule is followed. 
4.2 Non steroidal topical preparations 
This group includes: Calcipotriene/calcipotriol, Anthralin, Coal Tar, Tazarotene. 
4.2.1 Calcipotriene/calcipotriol 
These are vitamin D 3 derivatives used for chronic, moderately/severe Psoriasis of the scalp. 
The 0.005% solution is applied to the affected area and rubbed gently onto the scalp twice a 
day. Response to therapy takes about 8 weeks. It is not recommended in patients with acute 
psoriatic eruptions on the scalp, those with hypercalcemia or hypervitaminosis D. The main 
side effects are burning, itching, irritation and dryness. Irritation tends to decrease with 
time. Clearance has been observed even with 8 weeks of once a day treatment in up to 60% 
of patients. 
4.2.2 Anthralin 
Anthralin 0.1-3% cream has been used for long-term treatment of scalp Psoriasis. 
Concentration should be gradually increased according to body response and tolerance of 
the patient. Anthralin is applied in a thin layer to the psoriatic area once a day, rubbed in 
well and left on the scalp for 5-10 minutes before washing with a shampoo and rinsing well. 
It is not used for acutely inflamed scalp Psoriasis. Redness or irritation of the treated scalp is 
common. Anthralin may temporarily stain the fingernails, gray/white hair, skin and fabrics. 
Caution is advised in patients having history of allergy to anthralin or to condoms (e.g., 
parabens). 
4.2.3 Coal tar  
Coal tar is an effective and cheap treatment modality for scalp Psoriasis but staining and an 
acrid smell associated with its use may have an important impact on patients QOL. Topical 
tar solution (liquor picis carbonis-LPC,  or liquor carbonis detergens-LCD) is widely 
available and commonly used for scalp Psoriasis. Newer preparations specifically meant for 
scalp include coconut oil compound ointment (coal tar solution with precipitated sulfur, 
salicylic acid, coconut oil, yellow soft paraffin and emulsifying wax) and tar pomades 
(contain LCD, Tween 20 and salicylic acid in a hydrophilic ointment). Compound ointment 
should be applied once at night and washed off the next morning with a coal tar shampoo. 
Coal tar shampoos contain 1-20% coal tar extract. They are used twice a week. A tar blend 
1% shampoo Polytar (Steifel, Johannesburg, South Africa) is made of coal tar, juniper tar 
(cade oil) and pine tar. In a comparative 4-week study of tar blend 1% shampoo (Polytar) 
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and CP 0.05% shampoo (Clobex, Galderma, Ft. Worth, USA), the corticosteroid shampoo 
was significantly more effective and showed a better patient’s compliance too. 
Coal tar has been a very popular traditional treatment for various types of Psoriasis for over 
a century and still it’s the first-line treatment for scalp, hand, and foot Psoriasis. However, 
application of coal tar on hair invariably causes staining, which results in a high degree of 
patient non-compliance, especially in patients with non-black hair. Thus, treatment of scalp 
Psoriasis with a topical coal tar formulation requires that special concern to be paid to 
product esthetics. A novel lecithinized coal tar (LCT) formulation seems to be less likely to 
stain hair and thus has excellent potential to be exploited in treatment of scalp Psoriasis 
(Bhatia & al. 2011). 
4.2.4 Tazarotene 
There are no controlled studies on the use of tazarotene in scalp Psoriasis. Response to 
tazarotene (0.1%) compared to topical calcipotriol or steroids is less effective but relapse 
rates are reported to be minor as well. Dryness and irritation are common side effects. 
4.3 Combination therapies 
Combining different treatment allows enhanced efficacy and minimizes toxicity. 
Corticosteroids, when combined with vitamin D analogs, require a minor total amount of 
dose and induce less skin irritation. In treatment of moderate to severe plaque Psoriasis of 
the scalp, the fixed-combination suspension containing betamethasone 0.05% and 
calcipotriene 0.005% is used once a day. In a randomized double-blind controlled trial 
over 8 weeks, 71.2% patients achieved "absent" or "very mild" disease with the two-
compound scalp formulation, compared to 64% treated with betamethasone dipropionate, 
36.8% with calcipotriene and only 22.8% with the vehicle alone. Pruritus was the only 
adverse event reported. 
Topical steroids with Puvasol gave better results: 37.3% clearance versus 13.3% with Puvasol 
alone. LPC 10% along with 2% salicylic acid in a cream base along with Puvasol for 8 weeks 
gave a much better clearance rate than Puvasol alone. Tazarotene has also been found to be 
efficacious in combination with topical steroids and calcipotriol.  
In a prospective non-interventional trial in German dermatological practices, 721 patients 
with scalp Psoriasis received Xamiol(®) gel (calcipotriol 50 μg/g, betamethasone 0,5 mg/g) 
topically for 4 weeks. Severity was assessed by physician’s global assessment (PGA) and 
QOL was assessed by using a scalp-specific questionnaire at the beginning of the study and 
after 4 weeks treatment. The mean disease severity of scalp Psoriasis (PGA) improved from 
4.26 to 2.49 (-41.8 %, p < 0.0001) during 4 weeks treatment and QOL improved from 10.57 to 
3.22 (-69.5 %, p < 0.0001). Among patients with pre-treatment 89.5% of patients and 87.9% of 
dermatologists judged treatment response to Xamiol(®) gel as better/much better compared 
to previous therapy. Tolerability of Xamiol(®) gel was rated good/very good by 98 % of 
dermatologists and patients, respectively. The use of Xamiol(®) gel was found easy/very 
easy by 90.4 % of the patients (Mrowietz, 2011).  
McCormack (2001) reviewed the efficacy and tolerability of calcipotriol/betamethasone 
dipropionate in patients with Psoriasis vulgaris summarizing its pharmacological 
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properties. Calcipotriol/betamethasone dipropionate showed low systemic absorption and 
displayed local anti-inflammatory and immunoregulatory properties. It reduced 
hyperproliferation of keratinocytes and helped normalize keratinocyte differentiation. In 
large, well designed clinical trials, calcipotriol/betamethasone dipropionate, either as the 
ointment or the gel formulation, applied once a day for 4-8 weeks, was more effective than 
placebo, calcipotriol and tacalcitol, as well as betamethasone dipropionate in most instances, 
for the topical, symptomatic treatment of Psoriasis vulgaris of the trunk/limbs. Likewise, 
calcipotriol/betamethasone dipropionate gel applied once daily for 8 weeks was more 
effective than placebo or either component alone in the topical, symptomatic treatment of 
Psoriasis vulgaris of the scalp. Long-term, once a day, when required therapy with 
calcipotriol/betamethasone dipropionate for 52 weeks was more effective than calcipotriol 
alone for the treatment of scalp Psoriasis and was at least as effective as switching to 
calcipotriol for 48 weeks after 4 weeks of calcipotriol/betamethasone dipropionate or 
alternating between calcipotriol/betamethasone dipropionate and calcipotriol every 4 
weeks for 52 weeks in the treatment of Psoriasis vulgaris of the trunk/limbs. 
Calcipotriol/betamethasone dipropionate also improved health-related QOL.  
Calcipotriol/betamethasone dipropionate was generally well tolerated, with most 
adverse drug reactions being lesional or perilesional effects of mild or moderate severity 
(see Fig. 1).  
Calcipotriol/betamethasone dipropionate was often associated with fewer lesional/ 
perilesional adverse reactions than calcipotriol or tacalcitol and did not appear to be  
 
Fig. 1. Scalp Psoriasis after treatment with calcipotriol/betamethasone dipropionate gel 
formulation , applied once daily for 4 weeks. 
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associated with a higher incidence of corticosteroid-related adverse events during long-term 
therapy. Pharmaco-economic analyses predicted calcipotriol/betamethasone dipropionate 
to be more cost effective than other topical therapies. 
Puig & al. (2010) reported the recommendations developed by an expert panel using the 
Delphi process to reach a consensus and then ratified by the members of the Psoriasis Group 
of the Spanish Academy of Dermatology and Venereology. The recommended induction 
therapy for scalp Psoriasis is either a topical corticosteroid or a topical treatment combining 
calcipotriol and betamethasone. The choice of an appropriate vehicle is crucial in improving 
effectiveness and patient adherence to treatment. The only formulations that have been 
studied in long-term treatment of scalp Psoriasis are a combination of calcipotriol and 
betamethasone in gel and calcipotriol alone in solution. 
4.4 Second line treatments for recalcitrant disease 
These are used when all topical treatments fail. No controlled studies exist regarding their use 
and include phototherapy and systemic drugs like methotrexate, retinoids, cyclosporine and 
biologics. They are used based on physician experience, choice and risk versus benefit ratio. 
4.4.1 Phototherapy 
Hair blocks adequate penetration of ultraviolet light. Better results are achieved with 
conventional UV units, if hair is parted in many rows or if the patient has thin hair or if the 
head is shaved. Hand-held devices (UV combs) deliver a higher intensity of UV light. There 
are reports of the use of targeted phototherapy with excimer laser which provides 
narrowband ultraviolet B (NB-UVB) (308 nm) phototherapy with a very high irradiance, 
allowing for a shorter treatment time.   
4.4.2 Biologics 
The emergence of biologic therapies as an effective modality for treatment of plaque 
Psoriasis may provide another option for patients.  The biological agents employed in 
therapy of Psoriasis are classified into three groups (see Tab. 2). 
 
Inhibitors of tumor necrosis factor-α 
Adalimumab 
Certolizumab 
Etanercept 
Golimumab 
Infliximab 
Inhibitors of Interleukin-12 and Interleukin-23 
Ustekinumab 
Briakinumab 
T-cell modulating agents 
Alefacept 
Efalizumab 
Table 2. Biological agents employed in scalp Psoriasis. 
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Recent findings suggest that Efalizumab may be effective for treatment of head and neck 
Psoriasis (Krell & al., 2008). Katsambas (2009) recorded a PSSI score for 1150 patients at 
baseline and by week 12; there had been a median improvement in PSSI score of 73.3% (IQR 
33.3–94.3) compared with baseline. At week 12, PSSI 50 and PSSI 75 responses were 
achieved by 62.4% (718/1150) and 44.7% (514/1150) of patients, respectively. In many cases, 
a response to Efalizumab was apparent early in treatment, with over half of the patients 
classified as PSSI 50 responders at week 12 having already achieved this response by week 4 
(n = 425).  
However, Efalizumab has now been recommended for withdrawal in European market due 
to adverse effects. European Medicines Agency evaluated all safety data in light of post-
marketing surveillance of patients with Psoriasis receiving Efalizumab continuously for 
more than 3 years that showed opportunistic infections and, in particular, cases of JC virus 
infection (polyomavirus) resulting in progressive multifocal leucoencephalopathy (PML). It 
was concluded that the benefits of Efalizumab treatment no longer outweighed the risks 
associated with the drug and was recommended suspension of marketing authorization on 
19 February 2009. The drug has also been voluntarily withdrawn from the US market. 
Adalimumab, a monoclonal humanized tumor necrosis factor alpha inhibitor proved to be 
successful in treatment of severe facial Psoriasis (Noiles & Vender, 2008).  
Accumulating evidence supports efficacy and safety of ustekinumab for treatment of 
moderate to severe Psoriasis. There is some suggestion from head-to-head comparisons that 
ustekinumab may offer some advantage over TNF-α inhibitors. However, there is a need for 
larger and longer-term studies to assess the safety profile, cost-effectiveness and advantages 
of anti-interleukin 12 and 23 activity in the modern era of biological therapy (Garcia- 
Valladares & al., 2011). 
4.5 Miscellaneous agents 
Salicylic acid 5-10% is combined with other topical therapies as a keratolytic. Many topical 
treatments do not work well until thick scales that reduce drug penetration are removed. 
Urea 10% and lactic acid 10% have been used as scalp moisturizers. In resistant cases topical 
imidazole derivatives are used to control the overgrowth of Pityrosporum in scalp Psoriasis. 
Kircik (2011) stated that Salicylic acid 6% emollient foam provides a useful option that is 
highly effective, well tolerated and acceptable to patients. Efficacy, tolerability and patient 
acceptability of salicylic acid 6% emollient foam were assessed in an open-label pilot study 
of 10 subjects with scalp Psoriasis. All Psoriasis severity parameters were reduced with a 
significant decrease in PSSI score from 15.3 to 3.0 after four weeks of monotherapy 
(P<0.001). Sixty percent of subjects were either "completely cleared" or "almost cleared" from 
their Psoriasis. No adverse events were reported.  
Psoriasis skin lesions can be secondarily infected with bacteria according with Brook (Brook 
& al., 1999). In this report the predominant aerobic and facultative bacteria were S. aureus, 
group D Enterococcus and Escherichia coli while the predominant anaerobes were 
Peptostreptococcus spp. and Bacteroides spp., Propionibacterium acnes and pigmented 
Prevotella spp. in two each. Nineteen of the micro-organisms isolated from 78% patients 
produced lactamase.  
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The U.S. Food and Drug Administration (FDA) has approved two drugs, Protopic and 
Elidel, for treatment of eczema which many dermatologists have found to work well in 
treating Psoriasis of the face or of other sensitive areas.   
5. The aberrant epidermal-mesenchymal interactions theory   
The normal adult epidermis is a self-renewing tissue consisting of 10 to 20 layers in which 
cell proliferation is primarily restricted to the basal layer. Orthokeratinized epithelium 
similar to that in skin is seen in the hard palate, whereas other regions are either 
parakeratinized (gingiva) or nonkeratinized (buccal mucosa) (Squier & al., 1976). Injury to 
the epidermis activates a homeostatic response resulting in inflammation, re-
epithelialization, followed by tissue remodelling (Martin, 1997). Several studies have 
suggested release of interleukin-1 from keratinocytes at the wound site as the initial trigger 
for the inflammatory reaction. This serves as an autocrine signal to surrounding 
keratinocytes and paracrine signal to other cells, such as fibroblasts, endothelial cells, and 
lymphocytes resulting in a pleiotropic effect on them (Freedberg & al., 2001). The changes in 
gene expression that accompany re-epithelialization are similar to those seen in other 
disorders associated with hyperproliferation such as Psoriasis, contact dermatitis, and 
squamous cell carcinoma (SCC) suggesting considerable overlap in the signaling cascades. 
The development of a normal scar is dependent on the reversal of expression of these genes 
at the wound site. However, in some cases the inflammatory and proliferative signals persist 
even after wound closure resulting in pathological scars, such as hypertrophic (HTS) and 
keloid scars. Although most previous studies have considered these scars as dermal 
phenomena (Akagi & al., 1999), others have identified abnormalities associated with 
epidermal keratinocytes in HTS perhaps as a result of aberrant epidermal-mesenchymal 
interaction (Niessen & al., 2001). One of the most sensitive biochemical markers of 
terminal differentiation in keratinocytes is the keratin protein family that constitutes the 
major cytoskeletal architecture of all epithelia. In humans, the family consists of  30 
polypeptides (including trichocytic keratins of hair and nail) that are divided into two 
types; type I is acidic and includes K9 to K20; type II is basic/neutral and includes K1 to 
K8. The normal expression of K2e in the upper spinous and granular layers of 
interfollicular epidermis is increased in keloid scars but showed distinct down-regulation 
in Psoriasis and hypertrophic scars where keratinocytes are known to undergo activation. 
Unlike normal and psoriatic skin, K2e expression in hypertrophic and keloid scars began 
in the deepest suprabasal layer. In cutaneous basal and squamous cell carcinomas, K2e 
was absent in most tumor islands but the overlying epidermis showed strong expression. 
In mild-to-moderate oral dysplasia with orthokeratinization, K2e was highly expressed 
compared with parakeratinized areas but in severe dysplasia as well as in oral squamous 
cell carcinoma, K2e expression was undetectable. Taken together, the data suggest that 
K2e expression in skin is sensitive to keratinocyte activation but its up-regulation in oral 
lesions is a reflection of the degree of orthokeratinization (Bloor & al., 2003). K 15 protein 
and mRNA are primarily located in the basal keratinocytes of stratified tissues (Waseem 
al., 1999) and the k 15 gene is upregulated in human subjects where both alleles for k 14 
have beeen inactivated.  In hyperproliferating epidermis, such as in Psoriasis, K 15 
expression, both protein and mRNA, is downregulated, suggesting that K 15 expression 
may not be compatible with the activated phenotype. 
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6. The rare mucous occurrence and the PPP-tonsil-related disease 
6.1 Mucous membrane localization 
The occurrence of true psoriatic lesions on mucous membranes is disputed. For many years 
it has been claimed that this disease does not affect oral mucosa. Today it is thought that 
involvement of the oral cavity is rare but does exist. Oppenheim (1903) was the first to 
describe oral Psoriasis in a biopsy after histological examination. In a review of English-
language and European non-English literature Younai and Phelan (1997) identified only 57 
cases of oral Psoriasis. Since then, few new cases have been reported bringing the total to 
less than 100 cases described. The reports described a number of oral sites affected, such as 
lips, buccal mucosa, gums, palate, tongue and floor of the mouth. In the cases reviewed by 
Younai and Phelan, clinical  presentation was a white intraoral lesion in 44% of patients, 
erythematous in 24% and red and white mixed in 13%. The remaining lesions appeared 
ulcerative, vesicular, pustular, or indurated. The histopathological findings in oral mucous 
membranes are assumed to be similar to those found in skin lesions. Epithelial 
parakeratosis, elongated rete ridges and the presence of an inflammatory infiltrate of the 
upper dermis were described in most cases. Differential diagnosis from other oral diseases 
such as benign migratory glossitis, fissured tongue, oral candidosis and the oral lesions of 
Reiter’s syndrome may be subtle. The diagnosis is easily made when the clinical features of 
oral lesions parallels that of skin lesions and it is supported by histological investigation 
(Weathers et al., 1974; Younai and Phelan, 1997; Bruce and Rogers, 2003).  
6.2 Recurrent streptococcal infection theory in pathogenesis of psoriasis 
Recent immunological studies have shown that hyperactivation of tonsillar T cells is caused 
by a hyperimmune response to α-streptococci; recruitment of the T cells to lesions may be 
involved in the pathogenesis of PPP. ß1 integrin, expressed on T cells, not only provides a 
co-stimulatory signal for T-cell activation but also facilitates the accumulation of T cells in 
inflammatory skin lesions. In this study was found that expression of ß1 integrin on both 
tonsillar and peripheral blood CD4-positive T cells was higher in PPP patients than in non-
PPP patients. It was demonstrated that ß1 integrin may play a key role in the pathogenesis 
of PPP (Ueda & al., 2010).  
Psoriasis is a T-cell-mediated disease that can be triggered by group A beta-haemolytic 
streptococci infection. 
The results of many experimental studies provide evidence that Psoriasis is largely a T-cell 
mediated disorder. It may result from antigen-specific activation of T cells in the skin of 
genetically predisposed individuals. These T cells apparently have a particular functional 
differentiation and promote the psoriatic skin changes by secreting a certain set of cytokines. 
Based on the fact that streptococcal throat infections are a trigger of guttate Psoriasis, the 
putative psoriatic antigens are assumed to be in keratinocyte proteins that share structural 
homologies with streptococcal proteins and thus induce cross-reactive responses of 
antibacterial T cells against skin components. Together with the particular phenotype of 
psoriatic skin lesions these findings can suggest that Psoriasis represents a sterile 
antibacterial tissue reaction, which is mediated by streptococci-specific T cells that cross-
react against epidermal autoantigens. 
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Psoriasis is strongly associated with streptococcal throat infection and patients have 
increased occurrence of such infections. Psoriatic lesional T cells are oligoclonal, and T cells 
recognizing determinants common to streptococcal M-protein and keratin have been 
detected in patients’ blood. The streptococcal association might reflect the concurrence of 
superantigen production promoting skin-homing of tonsil T cells, M-protein mimicking 
keratin determinants, and adjuvant effects of the peptidoglycan. Accordingly, improvement 
of Psoriasis after tonsillectomy should be associated with fewer T cells that recognize keratin 
and streptococcal determinants (Valdimarsson & al., 2009). 
6.3 Tonsillectomy and antistreptococcal antibiotic therapy 
Tonsillectomy may be a successful treatment modality in selected patients with recalcitrant 
guttate or chronic plaque Psoriasis. In the study of Hone & al.  (1996) Psoriasis was cleared 
completely after tonsillectomy in five out of six patients (83%) with guttate Psoriasis and 
was improved in one patient. Two out of seven patients with plaque Psoriasis (29%) were 
cleared, two (29%) were improved and three (42%) were unchanged. 
Numerous studies implicate subclinical or recurrent streptococcal infection as a trigger or 
maintenance factor in the pathogenesis of Psoriasis in children but the study of Wilson & al. 
(2003) stated that the available evidence does not demonstrate the efficacy of either 
antibiotic therapy or tonsillectomy in treatment of childhood Psoriasis. Clinical trials 
assessing the efficacy of antibiotics or tonsillectomy as treatments for childhood Psoriasis 
were identified with a search of the medical literature and the results were compared. Only 
one controlled clinical trial was identified and it did not find a significant effect of antibiotic 
treatment on Psoriasis. In other studies, the percentage of Psoriasis patients who 
experienced a disease clearance with antibiotic therapy ranged from 0% to 55%, with no 
patients experiencing disease worsening during treatment. No controlled trials of 
tonsillectomy for Psoriasis were identified. The percentage of patients who experienced a 
disease clearance after tonsillectomy in uncontrolled trials ranged from 32% to 53% and a 
similar percentage reported significant improvement in their Psoriasis, with a maximum of 
7% noting worsening of the disease after operation.  
Owen & al. (2000) agreed on the previous conclusions. They searched the Cochrane Clinical 
Trials Register (Cochrane Library, Issue 3, 1999), Medline (1966- September 1999), Embase 
(1988-September 1999), the Salford Database of Psoriasis Trials (to November 1999) and the 
European Dermato-Epidemiology Network (EDEN) Psoriasis Trials Database (to November 
1999) for terms [STREPTOCOCC* or ANTIBIOTIC* or TONSIL*] and PSORIASIS using the 
Cochrane Skin Group search strategy. The only one eligible trial identified compared the use 
of two oral antibiotic schedules in 20 Psoriasis patients, predominantly of guttate type, who 
had evidence of beta-haemolytic streptococcal colonisation. Either rifampicin or placebo was 
added to the end of a standard course of antistreptococcal antibiotic 
(phenoxymethylpenicillin or erythromycin). No patient in either arm of the study improved 
during the observation period. No randomised trials of tonsillectomy for Psoriasis were 
identified. Although both antibiotics and tonsillectomy have frequently been advocated for 
patients with recurrent guttate Psoriasis or chronic plaque Psoriasis, there is no good 
evidence that either intervention is beneficial to date. 
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Because these treatments are relatively benign compared to other treatments for severe 
Psoriasis, the use of antibiotic therapy or tonsillectomy may still be worth considering, 
especially for those patients with recurrent streptococcal infections that seem to trigger or 
maintain their skin disease. 
6.4 Psoriasis as T cell-mediated disease and correlation with PPP 
Another item of correlation between Psoriasis and inflammatory disease of the upper 
aerodigestive tract is represented by PPP.  PPP is a tonsil-related disease and tonsillectomy 
is somewhat effective in treating the condition. However, aetiological association between 
tonsils disease and PPP has not been elucidated fully. Recently, some chemokines and 
chemokine receptors, including CC chemokine receptor (CCR) 4, CCR6 and CX chemokine 
receptor (CXCR) 3, have been reported to play important roles in the development of 
Psoriasis, which is related closely to PPP. Chemokines and chemokine receptors have been 
known to play a crucial role in directing the movement of mononuclear cells throughout the 
body, contributing to the pathogenesis of several skin diseases. In the skin lesions of PPP 
and/or Psoriasis, IL-8 and regulated upon activation normal T cell expressed and secreted 
are reported to be up-regulated on epidermal keratinocytes, suggesting that such 
chemokines may play an important role for migration of leucocytes and T cells.  
Yoshizaki & al.(2009) have demonstrated that: (1) CCR6 expression was up-regulated in 
both tonsillar and peripheral blood T cells; (2) CCR6 expression on tonsillar T cells was 
enhanced by in vitro stimulus with a-streptococcal antigens; (3) tonsillar T cells exhibit more 
intense chemotactic responses to CCL20; (4) the number of CCR6-positive peripheral blood 
T cells decreased after tonsillectomy and this reduction was correlated with an improvement 
in skin lesions; and (5) CCR6 expression of T cells and CCL20 expression of epidermal cells 
were up-regulated in PPP skin lesions.  
These results indicate that CCR6 may be induced by a novel immune response to α-
streptococci in tonsillar T cells in PPP patients. CCR6-positive tonsillar T cells may be 
recruited to the skin via peripheral blood circulation and then attracted to keratinocytes 
expressing CCL20 in the epidermis. Therefore, CCR6 may act as an important factor, 
bridging the tonsils and PPP. CCR6-positive tonsillar T cells may move and circulate in the 
peripheral blood, being recruited ultimately to the skin lesions of PPP patients. The 
mechanism underlying the manner in which CCR6-expressing tonsillar T cells are recruited 
to the skin lesions of PPP patients remains obscure; the skin-specific homing receptor CLA 
may play an important role. 
The pathogenic role of T lymphocytes and immune cross-reaction between human-HSP60 
and bacterial-HSP65 in PPP was also revealed (Hayashi & al. 2009). 
The evidence that T lymphocytes play a key role in the pathogenesis of Psoriasis is now 
compelling. Eruption of psoriatic skin lesions coincides with epidermal infiltration and 
activation of T cells and spontaneous or treatment-induced resolution of the lesions is 
preceded by the reduction or disappearance of epidermal T cells. An up-regulation has 
also been demonstrated for various molecules associated with T-cell mediated 
inflammation and treatments selectively directed against T cells have proved to be very 
effective. Infections with group A beta-haemolytic streptococci have been associated with 
onset of acute Psoriasis and exacerbation of chronic Psoriasis. Such infections are also 
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frequently accompanied by erythematous skin rashes. Also, recent reports indicate that 
streptococcal superantigens can induce expression of cutaneous lymphocyte antigens 
(CLA), believed to play a major role in enabling T cells to migrate to the skin.  A novel 
immune response to alpha-streptococci may enhance CLA expression on tonsillar T-cells 
through TGF-beta production in patients with PPP, resulting in moving of CLA-positive 
tonsillar T-cells to skin and tissue damages. This may play a key role in pathogenesis of 
PPP (Nozawa & al., 2005).  
Helper T-cells are frequently activated in tonsils from PPP patients and this activation may 
be related to unresponsiveness of TGF-beta1 by overexpression of Smad7. Such hyper-
activation of T-cell may increase the risk of elicitation of self-reactive T-cell, being associated 
with pathogenesis of PPP (Takahara & al., 2005). 
Furthermore, T-cell lines isolated from psoriatic lesions may show strong reactivity to 
streptococcal antigens. It was demonstrated that active Psoriasis is associated with a Th1 
type response to short peptides with epitopes shared by streptococcal M-protein and 
keratin. This is consistent with the hypothesis that Psoriasis may be induced and 
exacerbated in susceptible individuals by M-protein-specific Th1-like cells that cross-react 
with human epidermal keratin (Valdimarsson & al., 1997). 
6.5 Interaction between epidermal keratinocytes and the immune system 
Psoriasis is associated with an increase of Th17 cytokines, such as IL-17, IL-22, IL-21, and 
TNF-α, which are produced by Th 17 cells. Adipokines are peptide hormones or cytokines 
secreted from adipose tissues and involved in the pathogenesis of metabolic syndrome. 
Psoriasis patients have a high prevalence of metabolic syndrome. Increased serum levels of 
IL-22 and adiponectin were positively correlated with PASI. In contrast, serum high 
molecular weight adiponectin levels were decreased in Psoriasis and negatively correlated 
with PASI (Nakajima & al. 2011). 
Th 17 cells have crucial functions in host defense and dysregulated Th17 responses mediate 
a variety of autoimmune and inflammatory conditions. Th17 cells coexpress interleukin-22 
and its receptor is expressed on epidermal keratinocytes. IL-17 and IL-22 cooperatively 
enhance some immunological responses. A close relationship between IL-17 and the 
cutaneous milieu has been suggested by a number of observations. IL-17 induces the 
production of certain cytokines, chemokines and antimicrobial peptides by keratinocytes, 
and its cooperation with IL-22 has been documented. Recent findings have suggested that 
Th17 cells profoundly participate in the pathogenesis of certain skin disorders, in particular, 
Psoriasis. The concept of the subsets of T cells responsible for Psoriasis has been modified in 
the order of Th1, T cytotoxic 1, and again Thl, and Thl7 cells. IL-22 is the strongest cytokine 
in the keratinocyte-proliferative ability. Since IL-22 is produced by Th17 cells, they are 
crucial for the proliferation of keratinocytes. Furthermore, IL-22 with the help of IL-17 can 
induce the critical events of Psoriasis, including signal transducer and activator of 
transcription 3 (STAT3) activation, cytokine/chemokine (IL-8 etc.) production, and 
antimicrobial peptide elaboration. For maintaining Th17 cells, IL-23 is required and is 
released from tumor necrosis factor-alpha (TNF-alpha) and inducible nitric oxide synthetase 
(iNOS)-producing dendritic cells (TIP-DCs). TIP-DCs are activated via an autocrine 
mechanism by virtue of TNF-alpha.  
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The above cytokine network in the pathogenesis of Psoriasis has been proven by the 
therapeutic effectiveness of cytokine-blocking biologics. Antibodies against TNF-alpha or its 
soluble receptor have already been widely used in the treatment of Psoriasis.  
The involvement of Th17 cells has also been shown in allergen-specific immune responses. 
The percentage of Th17 cells is increased in the peripheral blood of patients with atopic 
dermatitis (AD) and associated with the severity of AD. Drug eruption is another disease 
where Th17 cells are involved in the pathogenesis. The percentage of circulating Th17 cells 
are increased in drug-induced hypersensitivity syndrome, etc. Th17 cells and IL-22 are 
increased in patients with acute generalized exanthematous pustulosis. Since IL-17 and IL-
22 cooperatively stimulate keratinocytes to produce IL-8, keratinocyte-derived IL-8 
contributes to the accumulation of neutrophils in the lesional epidermis of this drug 
eruption (Tokura & al., 2010). 
In conclusion, more recent data suggest that Psoriasis is caused by an interaction between 
epidermal keratinocytes and the immune system and that one possible candidate linking the 
immune system and epidermal keratinocytes is IL-22, a T-cell-derived cytokine that is 
produced by Th17 polarized T cells that are stimulated by IL-23, but that acts on epidermal 
keratinocytes to induce acanthosis and differentiation toward a psoriatic phenotype. 
Regardless of the specific underlying pathogenesis, Psoriasis is characterized by a 
disregulated epidermal acanthosis, dermal and epidermal leukocytic infiltration, and 
dilatation of dermal blood vessels—lesions that are maintained by the complex interplay  
between T cells and their cytokines, other leukocytes, vascular endothelium, and epidermal 
keratinocytes. As noted above, epidermal keratinocytes as well as vascular endothelial cells 
are active participants in the psoriatic inflammatory process via secretion of cytokines and 
growth factors, and the up regulation of signaling and adhesion molecules on their surfaces 
(Danilenko, 2008). 
6.6 SAPHO syndrome and CMRO 
SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome and CMRO (chronic 
recurrent multifocal osteomyelitis) represent pathologic entities related to Psoriasis and PPP 
in regard to the relationship between infection and autoimmunity. In genetically susceptible 
individuals, environmental factors (mainly infections) play a critical role in the pathogenesis 
of autoimmune diseases. Molecular similarity of microbial and host antigens has recently 
been proposed as a promoting factor for pathogen expansion when microbial agents are not 
recognized as alien and not completely eliminated (Rozin, 2009). 
SAPHO syndrome is now recognized as a distinct medical entity: a reactive infectious 
osteitis. Infectious agents isolated from SAPHO patients have gained special attention for 
many years. Their possible etiological role is supported by the pathogen isolation from 
different sites: anterior chest wall, spine, synovial fluid, bone tissue and skin pustules. A 
range of pathogens have been found, including Staphylococcus aureus, Hemophilus 
parainfluenzae, Actinomyces, and even Treponema pallidum (Arnson, 2008). 
Propionibacterium acnes is a much more frequent pathogen and plays a particular role. 
Multiple affected members who segregated a SAPHO syndrome-like phenotype had 
neutrophil dysfunction and reduced internal oxydant production (Ferguson & al., 2008). 
That may explain the inability of the innate system to eliminate the pathogen from 
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affected sites and justifies long-term or permanent antibiotic therapy (Rozin, 2009; 
Magrey, 2009). Treatment of SAPHO syndrome remains empirical as the underlying 
aetiopathogenesis is unclear. 
A growing body of literature has identified the association between neutrophilic dermatoses 
and multifocal, aseptic bone lesions in children, termed chronic recurrent multifocal 
osteomyelitis (CRMO). Classically, patients present with swelling, pain, and impaired 
mobility of the affected area, with skin lesions developing concurrently or in the future. 
Bone biopsy reveals inflammatory changes consistent with infectious osteomyelitis, but 
cultures and histologic staining invariably fail to identify an infectious source. Patients are 
refractory to antibiotic therapy, but dramatically respond to systemic steroids and may need 
to be maintained on low-dose steroids to prevent relapse. Numerous authors have 
suggested that CRMO and SAPHO syndrome lie along the same clinical spectrum (Tlougan, 
2009; Shilling, 2000). 
7. Psoriasis and tumours in head and neck area 
Overexpression of S100A7 (psoriasin), a small calcium-binding protein, has been associated 
with the development of Psoriasis and carcinomas in different types of epithelia but its 
precise functions are still unknown. Using human tissue specimens, cultured cell lines and a 
mouse model it was found (Zhou & al., 2008) that S100A7 is highly expressed in 
preinvasive, well-differentiated and early staged human squamous cell carcinoma of the 
oral cavity (SCCOC), but little or no expression was found in poorly differentiated, later-
staged invasive tumors. Interestingly those researchers showed that S100A7 inhibits both 
SCCOC cell proliferation in vitro and tumor growth/invasion in vivo. Furthermore, they 
demonstrated that S100A7 is associated with the beta-catenin complex, and inhibits beta-
catenin signaling by targeting beta-catenin degradation via a non canonical mechanism that 
is independent of GSK3beta-mediated phosphorylation. More importantly their studies also 
indicated that beta-catenin signaling negatively regulates S100A7 expression. Thus, this 
reciprocal negative regulation between S100A7 and beta-catenin signaling implies their 
important roles in tumor development and progression. Despite its high levels of expression 
in early stage of SCCOC tumorigenesis, S100A7 actually inhibits SCCOC tumor 
growth/invasion as well as tumor progression. Downregulation of S100A7 in later stages of 
tumorigenesis increases beta-catenin signaling, leading to promotion of tumor growth and 
tumor progression. 
Significantly increased risk of cancer was demonstrated in patients with Psoriasis at an 
average of 9.3 years after discharge from hospital. This risk, amounting to 1.4 times that in 
the general population, is mainly relative to skin and lung cancer in both sexes and to 
pharynx and larynx cancer in men. Still this data are not definitive as no studies have been 
published with bias correction for smoke and alcohol consumption. Non-melanoma skin 
cancer is the most common malignancy, occurring in 196 of 795 patients with cancer: 
standardized incidence ratio 2.4 for men and 2.6 for women. This means an overall lifetime 
risk (up to the age of 75 years) of 14.1%. Women run the highest risk of basal cell carcinoma 
in the age range 20-40 years, while men in the age range 30-60 years run a particularly high 
risk of squamous cell carcinoma (Frentz & Olsen, 1999).  
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Standardized incidence ratios (SIR) was found to be 2.80 (95% CI 1.96, 3.87) for oral cavity 
and pharynx cancer in a nationwide series of psoriasis patients from Sweden with a 
hospital discharge diagnosis of psoriasis made during 1965–83, who were alive and free 
from malignancy 1 year after first discharge, compared with the national population 
(Boffetta & al., 2001). Psoriasis was associated with a significantly increased prevalence 
ratio of lip, oral cavity and pharynx cancer (1.49; [1.22, 1.80]), in a national database in 
Taiwan (Tsai & al. 2011). 
8. Conclusion 
Psoriasis is a disease treated near exclusively from dermatologists.  Nevertheless some 
factors indicate the need for a new attention by the head and neck area specialists, especially 
by the otorhinolaringologists and maxillofacial surgeons.   
Recent literature focuses on relationship between autoimmunity and infection, the latter 
representing the prince environmental factor that could play a critical role in the 
pathogenesis of autoimmune diseases in susceptible individuals with the production of 
cross-reacting antibodies and the induction of the inflammatory second hit. When infectious 
agents  are not recognized as alien and not completely eliminated, pathogen expansion 
could be promoted by molecular similarity  of microbial and host antigens.  
As above mentioned important relationship has been demonstrated between tonsillar T cells 
and skin lesion in PPP patients with immune response to α-streptococci.  
Further investigations with translation from bench research to clinical knowledge and vice 
versa and with interrelation between dermatologists and head and neck specialists could 
result in considerable progress in understanding immunopathogenesis of Psoriasis and 
other immuno-mediated diseases.  
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